
A Starshinova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6713561/publications.pdf Version: 2024-02-01



Δ STARSHINOVA

#	Article	IF	CITATIONS
1	Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form. Pathogens, 2021, 10, 1408.	1.2	61
2	Sarcoidosis as an Autoimmune Disease. Frontiers in Immunology, 2019, 10, 2933.	2.2	57
3	Imbalance in B cell and T Follicular Helper Cell Subsets in Pulmonary Sarcoidosis. Scientific Reports, 2020, 10, 1059.	1.6	53
4	Small-fiber neuropathy definition, diagnosis, and treatment. Neurological Sciences, 2019, 40, 1343-1350.	0.9	48
5	Immunogenetic Predictors of Severe COVID-19. Vaccines, 2021, 9, 211.	2.1	40
6	New Coronaviral Infection: Features of Clinical Course, Capabilities of Diagnostics, Treatment and Prevention in Adults and Children. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2020, 19, 123-131.	0.1	30
7	RECOMBINANT TUBERCULOSIS ALLERGEN: 10 YEARS OF EXPERIENCE WITH THE TEST IN CHILDREN AND ADOLESCENTS IN THE RUSSIAN FEDERATION (META-ANALYSIS DATA). Pediatriia, 2020, 99, 121-129.	0.1	29
8	A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection. International Journal of Mycobacteriology, 2018, 7, 32.	0.3	25
9	EFFICACY OF NEW METHODS OF TUBERCULOSIS INFECTION IMMUNODIAGNOSTICS IN THE RUSSIAN FEDERATION. Pediatriia, 2019, 98, 229-235.	0.1	20
10	The opposite effect of human leukocyte antigen genotypes in sarcoidosis and tuberculosis: a narrative review of the literature. ERJ Open Research, 2020, 6, 00155-2020.	1.1	15
11	New laboratory criteria of the autoimmune inflammation in pulmonary sarcoidosis and tuberculosis. Clinical Immunology, 2021, 227, 108724.	1.4	13
12	Specific features of immune complexes in patients with sarcoidosis and pulmonary tuberculosis. Immunologic Research, 2018, 66, 737-743.	1.3	12
13	Small Fiber Neuropathy in Sarcoidosis. Pathophysiology, 2021, 28, 544-550.	1.0	11
14	Tuberculosis and autoimmunity: Common features. Tuberculosis, 2022, 134, 102202.	0.8	10
15	Molecular and Cellular Mechanisms of M. tuberculosis and SARS-CoV-2 Infections—Unexpected Similarities of Pathogenesis and What to Expect from Co-Infection. International Journal of Molecular Sciences, 2022, 23, 2235.	1.8	9
16	Efficacy of using bedaquiline in treatment of tuberculosis patients with multiple and extensive drug resistance. Tuberculosis and Lung Diseases, 2022, 100, 56-63.	0.2	8
17	Prospects for a COVID-19 treatment: review. Translational Medicine, 2020, 7, 30-37.	0.1	7
18	Altered peripheral blood Th17 and follicular T-helper subsets in patients with pulmonary tuberculosis. Russian Journal of Infection and Immunity, 2019, 9, 304-314.	0.2	6

Λ	C-		-	 		
A	ST	AR	SE	Ν(\mathcal{V}	А
	· · ·		· · ·	 		

#	Article	IF	CITATIONS
19	Autoimmune component in the etiology of sarcoidosis. Tuberculosis and Lung Diseases, 2020, 98, 54-62.	0.2	6
20	Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical) Tj ETQq0	0 0 rgBT /0	Dverlock 10 Tf

21	Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case) Tj ETQq1 1 0.78	34314 rgB 0.1	T /Overlock
22	The effect of human leukocyte Antigens-DRB1 alleles on development of different tuberculosis forms in children. International Journal of Mycobacteriology, 2018, 7, 117.	0.3	3
23	CHARACTERISTICS OF AUTOIMMUNE INFLAMMATION IN THE PATIENTS WITH LUNG TUBERCULOSIS. Medical Immunology (Russia), 2019, 21, 911-918.	0.1	3
24	TUBERCULOSIS IN CHILDREN IN THE NORTH-WEST REGION OF THE RUSSIAN FEDERATION: EPIDEMIOLOGY AND DIAGNOSTIC MEASURES EFFICACY. Pediatriia, 2019, 98, 274-279.	0.1	2
25	Diagnosis of Latent Tuberculosis Infection in Personnel of Various Institutions and Determination of the Risk Group for Tuberculosis. BIOpreparations Prevention Diagnosis Treatment, 2019, 19, 178-184.	0.2	2
26	TUBERCULOSIS UNDER CONDITIONS OF NOVEL CORONAVIRUS INFECTION. Pediatriia, 2021, 100, 153-157.	0.1	1
27	Immunotherapy in the Treatment of COVID-19. Pediatric Hematology/Oncology and Immunopathology, 2021, 20, 158-168.	0.1	0
28	Confirmation of preclinical data on tioureidoiminomethylpyridinium perchlorate in treatment of MDR-TB. , 2015, , .		0
29	The influence of genotype allele HLA-DRB1* on the development of generalized forms of tuberculosis among children. , 2015, , .		0
30	Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent. , 2019, , .		0